NU-6027

Research use only, not for human use.

NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.

NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively; inhibits human tumor cells with a mean GI50 of 10 ±6 uM; also inhibits cellular ATR (IC50=6.7 uM) and RAD51 focus formation, increases the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy.

NU6027 (1 nM-100 μM; 48 h) inhibits the growth of human tumor cells with a GI50 of 10±6 μM.NU6027 (0.1-25 μM; 24 h) inhibits ATR activity with an IC50 of 2.8 μM in GM847KD cells. NU6027 (1-10 μM; 24 h) inhibits ATR activity with an IC50 of 6.7±2.3 μM in MCF7 cells.NU6027 (4 or 10 μM; 24 h) attenuates G2/M arrest following DNA damage in MCF7 cells.NU6027 (10 μM; 24 h) significantly reduces RAD51 foci in both control and PF-01367338-treated V-C8 B2 cells.NU6027 (4 μM; 24 h) causes 82% suppression of the increase in RAD51 foci-positive cells treated by PF-01367338.Western Blot Analysis Cell Line:MCF7 cells Concentration:0, 1, 5, 10 μM Incubation Time:24 h Result:Inhibited CDK2-mediated pRbT821 by 42±27% compared with 70±12% inhibition of pCHK1S345 with the concentration of 10 μM.

——

NU6027 | NU 6027

Angiogenesis

CDK

ATR|CDK1|CDK2|DNA-PK

Other Indications

——

220036-08-8

251.3

C11H17N5O2

>98% (HPLC)

DMSO: 47 mg/mL (187 mM); Ethanol: 3 mg/mL (11.93 mM); Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

NC1=NC(OCC2CCCCC2)=C(N=O)C(N)=N1

6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine

(-20℃)

With Ice Pack

≥ 2 years